AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ORTHOCELL LTD

1.255

+0.0201.62%

Volume:1.26M

Turnover:1.61M

Market Cap:301.13M

PE:-78.74

High:1.335

Open:1.230

Low:1.210

Close:1.235

Loading ...

Overview Company News Filings

Trump Advisers Explore Closing, Reorganizing Bank Regulators, Report Says

ASX Market Close: Index dives to three week low | December 12, 2024

The Market Herald

Orthocell Secures First Orders for Nerve Repair Device in Singapore; Shares Up 5%

MT Newswires Live

Chris Judd’s Talk Ya Book: Orthocell building on ‘enormous potential’ with steady growth – and US push to come

The Market Herald

Orthocell Completes US Regulatory Study for Nerve Repair Product; Shares Hit All-Time High

MT Newswires Live

BRIEF-Orthocell Seeks Trading Halt

Orthocell Ltd - Seeks Trading Halt Pending Results of Regulatory Study Required for FDA Approval of Remplir

THOMSON REUTERS

Orthocell Taps Singaporean Distributor for Nerve Repair Device; Shares Hit New 52-Week High

MT Newswires Live

BUZZ-Australia's Orthocell hits more than 5-year high on Singapore expansion deal

BRIEF-Orthocell Says Appoints Exclusive Distributor In Singapore For Remplir

Orthocell - Device Technologies Asia Appointed Exclusive Distributor in Singapore for Remplir

THOMSON REUTERS

Pharma & Biotech Stocks on the Move in October

Orthocell Completes AU$17 Million Placement

MT Newswires Live

BUZZ-Australia's Orthocell falls most in more than 1-1/2 years on discounted placement

Orthocell Raises AU$17 Million for Remplir's US Launch, Further Growth

MT Newswires Live

BRIEF-Orthocell Says A$17M Placement To Drive Further Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OCC.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OCC.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","market":"AU","secType":"STK","nameCN":"ORTHOCELL LTD","latestPrice":1.255,"timestamp":1741583520000,"preClose":1.235,"halted":0,"volume":1261626,"delay":0,"changeRate":0.016194,"change":0.02,"floatShares":189223994,"shares":239947475,"eps":-0.015939,"lyrEps":-0.035547,"pbRate":15.33,"amount":1611957,"amplitude":0.101215,"volumeRatio":0.9224468905174064,"dividePrice":0,"prevYearClose":1.355,"fiveDayClose":1.315,"twentyDayClose":1.68},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","floatShares":189223994,"roa":"-20.32%","roe":"-29.77%","lyrEps":-0.035547,"volumeRatio":0.9224468905174064,"shares":239947475,"dividePrice":0,"high":1.335,"amplitude":0.101215,"preClose":1.235,"low":1.21,"week52Low":0.35,"pbRate":"15.33","psRate":"47.69","week52High":1.79,"institutionHeld":0,"latestPrice":1.255,"committee":-0.667497,"eps":-0.015939,"divideRate":0,"volume":1261626,"delay":0,"ttmEps":-0.015939,"open":1.23,"prevYearClose":1.355,"prevWeekClose":1.235,"prevMonthClose":1.295,"prevQuarterClose":1.355,"fiveDayClose":1.315,"twentyDayClose":1.68,"sixtyDayClose":0.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OCC.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2491370411","title":"Trump Advisers Explore Closing, Reorganizing Bank Regulators, Report Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2491370411","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491370411?lang=en_us&edition=fundamental","pubTime":"2024-12-13 22:48","pubTimestamp":1734101337,"startTime":"0","endTime":"0","summary":"The Trump transition team is exploringa range of financial sector reforms,The Wall Street Journal reported, including shutting theFederal Deposit Insurance Corp.Trump advisers have also also discussed plans to either combine or restructure the main federal bank regulators.Some of the ideas would require congressional action to enact.President-elect Donald Trump's transition team is exploring a range of financial sector reforms including shutting theFederal Deposit Insurance Corp. ,The Wall Street Journal reported.According to the Journal's report, Trump advisers and officials from his new Department of Government Efficiency , the advisory group co-chaired by Elon Musk and Vivek Ramaswamy, have in interviews with potential nominees to lead bank regulatory agencies asked whether the president-elect could abolish the watchdog.Trump advisers and potential nominees have also \"discussed plans to either combine or otherwise restructure\" the main federal bank regulators: the FDIC, the OCC and ","market":"hk","thumbnail":"https://www.investopedia.com/thmb/THo8M96fg-Op5jRmPulyo22ItPA=/6240x4160/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2187500032-4eae907561e74cefbb334b32ef093e70.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/THo8M96fg-Op5jRmPulyo22ItPA=/6240x4160/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2187500032-4eae907561e74cefbb334b32ef093e70.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/trump-advisers-explore-closing-reorganizing-bank-regulators-report-says-8760978","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["US30Y.BOND","US3Y.BOND","US12M.BOND","US5Y.BOND","OCC.AU","BK4020","BK7508","US6M.BOND","US10Y.BOND","US7Y.BOND","OCC","BK7067","US2Y.BOND"],"gpt_icon":0},{"id":"2490419820","title":"ASX Market Close: Index dives to three week low | December 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490419820","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490419820?lang=en_us&edition=fundamental","pubTime":"2024-12-12 14:35","pubTimestamp":1733985300,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.28% at 8,330 points – finishing the session at a three-week low.Jobs data today surprised analysts, with unemployment falling to 3.9%. Now the odds of an early interest rate cut have lengthened, and the Aussie dollar jumped in response. Analysts say the labour market poses minimal inflationary risk, but the RBA remains vigilant to prevent possible rebounds in underlying inflation.Economists have revised their predictions on rates, with the ANZ now predicting the first rate cut in May, while EY has predicted an initial cut in Q2.Industrials was the biggest loser, down 1.1%, followed by Telecommunication, down 1%, and Industrials, down 0.75%.Information Technology was the only substantive biggest winner, up 0.4%.Capstone Copper  closed up 1.6% after Citi initiated coverage with a “buy” rating, citing “positive earnings momentum” with a price target of $13.60. Feeding into Citi’s rating is its forecast of a US$10,000 per tonne copper price.Orthocell  closed up 4.0","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-dives-to-three-week-low-december-12-2024-2024-12-12/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","BPT.AU","CSC.AU","PWR.AU","BK7110","BK7064","DOW.AU","BK7507","BK7055","VNT.AU","BK7143","BK7142","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2490810271","title":"Orthocell Secures First Orders for Nerve Repair Device in Singapore; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490810271","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490810271?lang=en_us&edition=fundamental","pubTime":"2024-12-12 08:27","pubTimestamp":1733963272,"startTime":"0","endTime":"0","summary":"Orthocell  received the first orders for its peripheral nerve repair device Remplir in Singapore as it advanced its commercialization activities in the market, according to a Thursday filing with the Australian bourse.The product is set for launch in the first quarter of 2025 via distributor Device Technologies Asia, which also handles the distribution of Remplir in Australia and New Zealand, the filing said.The company's shares were up almost 5% in recent Thursday trade.Price : $1.05, Change: $+0.05, Percent Change: +4.50%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK7067","BK7508","BK4125","LU0345774631.USD","LU1043141123.HKD","LU0426412945.USD","OCC.AU","LU0994945656.USD","XKO.AU","LU2238339852.HKD","AUD","LU0426417589.USD","XAO.AU"],"gpt_icon":0},{"id":"2488133387","title":"Chris Judd’s Talk Ya Book: Orthocell building on ‘enormous potential’ with steady growth – and US push to come","url":"https://stock-news.laohu8.com/highlight/detail?id=2488133387","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488133387?lang=en_us&edition=fundamental","pubTime":"2024-12-04 12:54","pubTimestamp":1733288040,"startTime":"0","endTime":"0","summary":"OnChris Judd’sTalk Ya Book today, the AFL legend sat down with Orthocell Limited  chairman John Van Der Wielen to talk about the “overnight success” of the ASX-listed biotech company and its bright future.“We wanted to start at the top and get a strong board with the right expertise,” Mr Van Der Wielen told Mr Judd. These pickups included Professor Fiona Woods AM, the Hon. Kim Beazley, as well as Dr. Ravi Thadhani, the latter of whom is the executive vice president at Emory University which boasts 35,000 employees.Orthocell has two main products already in the chamber: A ‘grow your own bone’ dental scaffolding and Remplir, a nerve repair collagen preparing for a U.S. launch.Both have begun shipping in countries like Austria, Germany, and Singapore, with rollouts continuing in Australia and New Zealand – and Mr Van Der Wielen believes Orthocell’s global expansion can only sell confidence.In 2023, Chris joined the people he interviews in the world of funds management by creating the Ceru","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/chris-judds-talk-ya-book-orthocell-building-on-enormous-potential-with-steady-growth-and-us-push-to-come-2024-12-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4022","BK7508","BK4230","BK7002","CAR","OCC.AU","BK7503","CAR.AU","BK7067"],"gpt_icon":0},{"id":"2488616300","title":"Orthocell Completes US Regulatory Study for Nerve Repair Product; Shares Hit All-Time High","url":"https://stock-news.laohu8.com/highlight/detail?id=2488616300","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488616300?lang=en_us&edition=fundamental","pubTime":"2024-12-02 09:13","pubTimestamp":1733102030,"startTime":"0","endTime":"0","summary":"Orthocell  completed its US Food and Drug Administration 510 regulatory study for Remplir, a collagen wrap product used in peripheral nerve repair, according to a Monday filing with the Australian bourse.The regulatory study is a crucial part of Orthocell's application with the US FDA for marketing clearance for Remplir, the filing said.The study met all endpoints, showing Remplir enables consistent and predictable recovery of upper arm and hand function following nerve repair. Clinical results showed 85% of nerve repairs with Remplir achieved functional muscle recovery 24 months post-treatment.The regenerative medicine company plans to submit its 510 application this month, with US FDA clearance expected in the first quarter of 2025.Remplir is already approved in Singapore, Australia, and New Zealand. The company plans to launch the product in Canada, the UK, Europe, and other ASEAN markets.Orthocell's shares rose nearly 10% in recent Monday trade and earlier hit an all-time high.Pric","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426412945.USD","BK7067","LU0426417589.USD","LU0994945656.USD","XAO.AU","XJO.AU","AUD","XKO.AU","BK7508","LU0345774631.USD","LU2238339852.HKD","BK4125","OCC.AU","LU1043141123.HKD"],"gpt_icon":0},{"id":"2487329769","title":"BRIEF-Orthocell Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2487329769","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487329769?lang=en_us&edition=fundamental","pubTime":"2024-11-29 06:26","pubTimestamp":1732832762,"startTime":"0","endTime":"0","summary":"Nov 29 (Reuters) - Orthocell Ltd   :   * SEEKS TRADING HALT PENDING RESULTS OF REGULATORY STUDY REQUIRED FOR FDA APPROVAL OF REMPLIR Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2487329755","title":"Orthocell Ltd - Seeks Trading Halt Pending Results of Regulatory Study Required for FDA Approval of Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2487329755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487329755?lang=en_us&edition=fundamental","pubTime":"2024-11-29 06:25","pubTimestamp":1732832745,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241128:nFWN3MZ0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2486604298","title":"Orthocell Taps Singaporean Distributor for Nerve Repair Device; Shares Hit New 52-Week High","url":"https://stock-news.laohu8.com/highlight/detail?id=2486604298","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486604298?lang=en_us&edition=fundamental","pubTime":"2024-11-27 11:44","pubTimestamp":1732679054,"startTime":"0","endTime":"0","summary":"Orthocell  signed up Device Technologies Asia as its exclusive distributor for nerve repair damage device Remplir for the Singaporean market, according to a Wednesday filing with the Australian bourse.First sales from the new market are anticipated in the first quarter of 2025, the filing said.Device Technologies is currently the distributor of Remplir in Australia and New Zealand, as per the filing.The company's shares surged nearly 19% in recent Wednesday trade and earlier hit a new 52-week high.Price : $0.76, Change: $+0.12, Percent Change: +18.75%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0994945656.USD","BK7508","LU2238339852.HKD","XKO.AU","LU0426417589.USD","XAO.AU","XJO.AU","LU0426412945.USD","OCC.AU","BK7067","LU0345774631.USD","BK4125","AUD","LU1043141123.HKD"],"gpt_icon":0},{"id":"2486486467","title":"BUZZ-Australia's Orthocell hits more than 5-year high on Singapore expansion deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2486486467","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486486467?lang=en_us&edition=fundamental","pubTime":"2024-11-27 10:49","pubTimestamp":1732675777,"startTime":"0","endTime":"0","summary":"** Orthocell    jumps as much as 21.1% to A$0.775, highest since May 9, 2019   ** Stock logs biggest intraday pct jump since early October   ** Biotech firm signs distributorship agreement with Singapore-based Device Technologies Asia for exclusive distribution of its nerve repair device Remplir   ** OCC expects first sales of the device in first quarter of 2025   ** Around 2.3 mln shares traded, 3.2x the 30-day avg   ** Stock up ~87% YTD ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2486856541","title":"BRIEF-Orthocell Says Appoints Exclusive Distributor In Singapore For Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2486856541","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486856541?lang=en_us&edition=fundamental","pubTime":"2024-11-27 07:10","pubTimestamp":1732662610,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Says Appoints Exclusive Distributor In Singapore For RemplirNov 27 (Reuters) - Orthocell Ltd OCC.AX:DEVICE TECHNOLOGIES ASIA APPOINTED EXCLUSIVE DISTRIBUTOR IN SINGAPORE FOR REMPLIRFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nFWN3MX146:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2486830142","title":"Orthocell -  Device Technologies Asia Appointed Exclusive Distributor in Singapore for Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2486830142","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486830142?lang=en_us&edition=fundamental","pubTime":"2024-11-27 06:07","pubTimestamp":1732658876,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nFWN3MX146:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2482719215","title":"Pharma & Biotech Stocks on the Move in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2482719215","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482719215?lang=en_us&edition=fundamental","pubTime":"2024-11-11 08:47","pubTimestamp":1731286073,"startTime":"0","endTime":"0","summary":"The Pharma & Biotech market had a relatively muted month. There were a number of companies that experienced strong share price movements but this was on limited newsflow and limited liquidity. Below we take a look at 4 Pharma & Biotech companies whose share prices rallied in October on the back of positive announcements.Nyrada’s share price rose 84.6% in October on the back of the announcement that the preclinical study for the Company’s lead drug candidate NYR-BI03 had shown strong efficacy limiting cardiovascular damage associated with coronary heart disease. NYR-BI03 demonstrated superior efficacy compared to Captopril, an FDA-approved therapy, although we note that this is a preclinical study. The results potentially expand the use of NYR-BI03 with myocardial infarction a leading cause of morbidity and mortality worldwide.Straite+ is currently sold in US, Canada, Europe, UK, Australia and New Zealand with Remplir sold in Australia, New Zealand and recently receiving approval for sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/pharma-biotech-stocks-on-the-move-in-october-2024-11-10","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/pharma-biotech-stocks-on-the-move-in-october-2024-11-10","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["OCC.AU","BK7067","BK7508","RSH.AU","RPM.AU","NYR.AU","BK4109","TYP.AU","BK7007","BK7051","BK7096","BK7503","RPM"],"gpt_icon":0},{"id":"2480043085","title":"Orthocell Completes AU$17 Million Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2480043085","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480043085?lang=en_us&edition=fundamental","pubTime":"2024-11-01 11:13","pubTimestamp":1730430780,"startTime":"0","endTime":"0","summary":"Orthocell (ASX:OCC) raised AU$17 million via the placement of 28.3 million shares priced at AU$0.60 apiece, according to a Thursday filing with the Australian Securities Exchange.Proceeds will be used","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","LU2238339852.HKD","LU0426417589.USD","AUD","OCC.AU","BK7508","LU0994945656.USD","XAO.AU","XJO.AU","BK7067","LU0345774631.USD","LU1043141123.HKD","LU0426412945.USD","XKO.AU"],"gpt_icon":0},{"id":"2478264426","title":"BUZZ-Australia's Orthocell falls most in more than 1-1/2 years on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2478264426","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478264426?lang=en_us&edition=fundamental","pubTime":"2024-10-25 11:11","pubTimestamp":1729825915,"startTime":"0","endTime":"0","summary":"** Shares of Orthocell    fall as much as 10.1% to A$0.620, posting their biggest intraday pct loss since March 16, 2023   ** Biotech firm says it will raise A$17 mln  via placement of 28.3 mln shares   ** Issue price of A$0.60 per share is at a 13% discount to stock's last close   ** Co says funds will be used to launch its nerve repair medical device Remplir in the United States   ** Stock hits lowest level since Oct. 14   ** About 1.2 mln shares change hands, 1.5x the 30-day avg   ** Stock up 62.3% YTD, as of 0308 GMT ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","XKO.AU","XAO.AU","XJO.AU","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2478246644","title":"Orthocell Raises AU$17 Million for Remplir's US Launch, Further Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2478246644","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478246644?lang=en_us&edition=fundamental","pubTime":"2024-10-25 11:11","pubTimestamp":1729825865,"startTime":"0","endTime":"0","summary":"Orthocell  raised AU$17 million via the placing of 28,333,333 shares at AU$0.60 apiece to launch collagen nerve wrap Remplir in the US and to drive further growth.The issue price represented a 12% discount to the 10-day volume weighted average price, according to a Friday filing with the Australian bourse.Shares under the placement will be allotted on Oct. 31, the filing said.Orthocell said it remains on schedule to release top-line results from its Remplir US market authorization study and submit its US market authorization application in the fourth quarter, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2478361226","title":"BRIEF-Orthocell Says A$17M Placement To Drive Further Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2478361226","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478361226?lang=en_us&edition=fundamental","pubTime":"2024-10-25 09:04","pubTimestamp":1729818279,"startTime":"0","endTime":"0","summary":"Oct 25 (Reuters) - Orthocell Ltd   :   * $17M PLACEMENT TO DRIVE FURTHER GROWTH AS US APPROVAL NEARS   * PLACEMENT AT A$0.60 PER SHARE   * ALL FIGURES IN AUDFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":2,"totalSize":52}]}}